Previous 10 | Next 10 |
United Therapeutics (UTHR) has announced that its Tyvaso DPI (inhaled treprostinil) met its primary objective of demonstrating safety and tolerability in patients with pulmonary arterial hypertension (“PAH”) transitioning from Tyvaso (treprostinil) inhalation solution.In a separ...
United Therapeutics Announces BREEZE Study of Investigational Tyvaso DPI™ Meets Primary Objective Study demonstrated safety and tolerability of Tyvaso DPI™ in patients with PAH transitioning from Tyvaso® Inhalation Solution A separate study in healthy volu...
Demonstration of high rate, micron-level printing capability enabling vascularization required to sustain living cells Critical technology elements reach level required to dramatically expand application opportunities in human body Pathway for accelerated new drug therapy developm...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
United Therapeutics ([[UTHR]] +2.5%) has announced that the results from INCREASE clinical study evaluating Tyvaso (treprostinil) inhalation solution for pulmonary hypertension associated with interstitial lung disease (PH-ILD), were published in the New England Journal of Medicine.Resul...
United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease INCREASE Study is First to Demonstrate a Clear Benefit in Patients with PH-ILD, a Life-thre...
United Therapeutics Corporation To Present At The 39th Annual J.P. Morgan Healthcare Conference PR Newswire SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Jan. 4, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today...
NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the tr...
United Therapeutics (UTHR) inks agreement to purchase a Rare Pediatric Disease Priority Review Voucher ((PRV)) for $105M to use with a forthcoming New Drug Application ((NDA)) for Tyvaso DPI, expected in H1 2021.The PRV entitles the holder to designate an NDA for priority review and provides ...
United Therapeutics Announces Agreement To Acquire Priority Review Voucher Voucher expected to be applied to the forthcoming NDA for Tyvaso DPI™ PR Newswire SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Dec. 28, 2020 /PRNewswire/ -- Un...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...